Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection
about
A complex systems approach to evaluate HIV prevention in metropolitan areas: preliminary implications for combination intervention strategiesFrailty, HIV infection, and mortality in an aging cohort of injection drug usersIncreases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada.Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008Examining non-AIDS mortality among people who inject drugs.Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients.The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.Benefits of adherence to psychotropic medications on depressive symptoms and antiretroviral medication adherence among men and women living with HIV/AIDS.Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.Prevention of HIV infection among injection drug users in resource-limited settings.Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United StatesIncarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy.Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIVProvider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers.The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations.Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems.Integrating HIV prevention activities into the HIV medical care setting: a report from the NYC HIV Centers Consortium.Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS.Mortality among heroin users and users of other internationally regulated drugs: A 27-year follow-up of users in the Epidemiologic Catchment Area Program household samples.Mortality among people who inject drugs: a systematic review and meta-analysis.Nonstructured treatment interruptions among injection drug users in Baltimore, MD.Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.Social and structural factors associated with HIV disease progression among illicit drug users: a systematic reviewUnderstanding the effects of different HIV transmission models in individual-based microsimulation of HIV epidemic dynamics in people who inject drugs.Persistent racial/ethnic disparities in AIDS diagnosis rates among people who inject drugs in U.S. metropolitan areas, 1993-2007.Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death.Improving survival among HIV-infected injection drug users: how should we define success?Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.The effects of low literacy and cognitive impairment on medication adherence in HIV-positive injecting drug users.
P2860
Q28483747-E3D9CCFA-D9DF-4FFA-993D-E3D73A7AF785Q28485898-A78C1C4A-6BA3-4CFA-B1F8-811BCE925D03Q30399058-F7966D44-5475-4EF6-8B26-D1E9E07D270BQ33867166-C905F49D-06E5-45BE-8D24-CAA0F26D61ECQ34585154-AB0D795A-446E-4A11-A7F4-7F1D48BE1094Q34666176-25BCCFD1-CCDE-43AE-9F4C-095E0C79918CQ34731327-BD5550E6-2F3A-4482-BF72-2BB9B3254E74Q34845860-353CE67B-E49F-4A0D-9484-B9D3DD831B31Q34997577-2E73044D-838B-483E-9747-270E90C26DDEQ35043964-3ED2FBF7-2D30-4FAE-8DD7-A70BA50A2701Q35058786-AF49DD5F-E373-4FFE-9736-6ED5E5146E5DQ35452380-92E252C9-12DC-4123-8397-D9C587521DDCQ35799636-942CF77C-37E1-4722-9426-C117614AF003Q35835854-153E475B-1BE7-420E-9809-68C5087A97F0Q36249104-FE254BC3-7E18-4F80-8B04-562E8DB522AAQ36468227-12CE9BDA-DAC8-43A8-A3D2-090BE4D27161Q36482434-FAA83BE8-F162-4E55-BE90-3A85A20DE6B5Q36492802-157EF1D6-660C-45A7-9BD0-CF60DD81F67BQ36676321-62608A53-10AF-4A9A-878F-6C17BB120936Q36706977-FD3A247F-D8E7-4978-B008-D6D95A2E3AC3Q37434895-BA88D1FF-AD51-4B46-9CDD-05B2CFF85A0AQ37550334-73F39411-F424-4174-B208-A625E91681DEQ37638817-6F5D6051-52CC-4BFD-9149-5BD0DE08AA85Q37661224-161A673F-446C-4C35-B67F-A084EB3BCB46Q37696114-D7EBCB9A-3470-4579-AA09-F4770A08E4B1Q39751709-C82154F6-365B-4B52-A3C0-798D92148735Q42717658-271259D7-654F-49E6-95D3-D84DF496E9A2Q43617569-8FCC8DC1-A855-4737-BB7D-0BBC1D66F585Q46244156-28946565-1052-4EC4-B6A7-34B6512C231D
P2860
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Effectiveness of highly active ...... munodeficiency virus infection
@ast
Effectiveness of highly active ...... munodeficiency virus infection
@en
type
label
Effectiveness of highly active ...... munodeficiency virus infection
@ast
Effectiveness of highly active ...... munodeficiency virus infection
@en
prefLabel
Effectiveness of highly active ...... munodeficiency virus infection
@ast
Effectiveness of highly active ...... munodeficiency virus infection
@en
P2093
P2860
P356
P1476
Effectiveness of highly active ...... munodeficiency virus infection
@en
P2093
Greg M Lucas
Gregory D Kirk
Noya Galai
Sandro Galea
Timothy R Sterling
P2860
P304
P356
10.1093/AJE/KWI133
P407
P577
2005-06-01T00:00:00Z